$2.85 Billion is the total value of Tekla Capital Management LLC's 200 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 36.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | Buy | Alexion Pharmaceuticals, Inc. | $78,423,000 | +156.9% | 501,942 | +88.1% | 2.76% | +140.9% |
| UNH | Buy | Unitedhealth Group Incorporated | $76,864,000 | +32.7% | 219,185 | +18.0% | 2.70% | +24.5% |
| BMY | Buy | Bristol Myers Squibb Company | $61,404,000 | +7.8% | 989,908 | +4.7% | 2.16% | +1.1% |
| BIIB | Buy | Biogen Inc. | $60,442,000 | -0.3% | 246,844 | +15.5% | 2.12% | -6.5% |
| TMO | Buy | Thermo Fisher Scientific Inc. | $59,412,000 | +356.7% | 127,553 | +333.0% | 2.09% | +328.7% |
| SGEN | New | Seagen Inc. | $51,424,000 | – | 293,619 | +100.0% | 1.81% | – |
| DHR | Buy | Danaher Corporation | $48,835,000 | +235.7% | 219,840 | +225.4% | 1.72% | +214.9% |
| ABT | Buy | Abbott Laboratories | $47,206,000 | +17.4% | 431,145 | +16.7% | 1.66% | +10.1% |
| LLY | Buy | Eli Lilly and Company | $40,106,000 | +52.5% | 237,537 | +33.7% | 1.41% | +43.0% |
| ZBH | Buy | Zimmer Biomet Holdings, Inc. | $32,977,000 | +26.2% | 214,014 | +11.5% | 1.16% | +18.4% |
| HCA | Buy | HCA Healthcare, Inc. | $28,796,000 | +181.9% | 175,097 | +113.7% | 1.01% | +164.2% |
| CI | Buy | Cigna Corporation | $28,253,000 | +134.1% | 135,712 | +90.5% | 0.99% | +119.7% |
| NBIX | Buy | Neurocrine Biosciences, Inc. | $28,202,000 | +364.0% | 294,234 | +365.5% | 0.99% | +334.6% |
| RMD | Buy | ResMed Inc. | $28,131,000 | +69.0% | 132,344 | +36.3% | 0.99% | +58.3% |
| DXCM | Buy | DexCom, Inc. | $27,597,000 | +261.0% | 74,643 | +302.5% | 0.97% | +239.2% |
| EXEL | Buy | Exelixis, Inc. | $25,218,000 | -5.8% | 1,256,520 | +14.7% | 0.89% | -11.7% |
| MCK | Buy | McKesson Corp. | $22,688,000 | +41.7% | 130,448 | +21.3% | 0.80% | +32.8% |
| PRAH | Buy | PRA Health Sciences, Inc. | $22,057,000 | +173.4% | 175,838 | +121.1% | 0.78% | +156.6% |
| ARNA | Buy | Arena Pharmaceuticals, Inc. | $19,436,000 | +61.8% | 252,971 | +57.5% | 0.68% | +51.8% |
| MRTX | Buy | Mirati Therapeutics, Inc. | $18,402,000 | +40.7% | 83,784 | +6.3% | 0.65% | +32.0% |
| ALLK | Buy | Allakos Inc. | $18,331,000 | +249.5% | 130,937 | +103.3% | 0.64% | +226.9% |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $17,737,000 | +71.5% | 331,789 | +32.3% | 0.62% | +60.6% |
| ADPT | Buy | Adaptive Biotechnologies Corporation | $16,912,000 | +1307.0% | 286,013 | +1057.2% | 0.59% | +1220.0% |
| STRO | Buy | Sutro Biopharma, Inc. | $15,252,000 | +136.6% | 702,523 | +9.6% | 0.54% | +121.5% |
| TPTX | Buy | Turning Point Therapeutics, Inc. | $14,540,000 | +2831.5% | 119,324 | +2001.9% | 0.51% | +2589.5% |
| SYNH | Buy | Syneos Health, Inc.class a | $13,295,000 | +131.6% | 195,136 | +80.7% | 0.47% | +117.2% |
| SAGE | Buy | Sage Therapeutics, Inc. | $13,153,000 | +123.7% | 152,040 | +58.0% | 0.46% | +110.0% |
| Buy | Trillium Therapeutics Inc. | $12,030,000 | +88.9% | 817,784 | +82.5% | 0.42% | +77.0% | |
| ITCI | Buy | Intra-Cellular Therapies, Inc. | $11,644,000 | +381.6% | 366,176 | +288.6% | 0.41% | +349.5% |
| TDOC | New | Teladoc Health, Inc. | $11,302,000 | – | 56,520 | +100.0% | 0.40% | – |
| GMAB | Buy | Genmab A/Ssponsored ads | $10,518,000 | +55.5% | 258,672 | +40.0% | 0.37% | +45.7% |
| ARWR | Buy | Arrowhead Pharmaceuticals, Inc. | $10,196,000 | +219.2% | 132,886 | +79.1% | 0.36% | +198.3% |
| KURA | Buy | Kura Oncology, Inc. | $8,931,000 | +391.3% | 273,463 | +360.8% | 0.31% | +361.8% |
| KRTX | Buy | Karuna Therapeutics, Inc. | $8,659,000 | +167.7% | 85,236 | +103.8% | 0.30% | +151.2% |
| NVAX | Buy | Novavax, Inc. | $8,540,000 | +583.7% | 76,585 | +564.6% | 0.30% | +538.3% |
| EXAS | Buy | Exact Sciences Corporation | $8,413,000 | +444.5% | 63,502 | +319.2% | 0.30% | +410.3% |
| TBPH | Buy | Theravance Biopharma, Inc. | $8,108,000 | +83.7% | 456,296 | +52.9% | 0.28% | +72.7% |
| OMI | New | Owens & Minor, Inc. | $7,196,000 | – | 266,023 | +100.0% | 0.25% | – |
| TGTX | New | TG Therapeutics, Inc. | $6,933,000 | – | 133,269 | +100.0% | 0.24% | – |
| ARVN | New | Arvinas, Inc. | $6,239,000 | – | 73,459 | +100.0% | 0.22% | – |
| DNLI | New | Denali Therapeutics Inc. | $6,059,000 | – | 72,333 | +100.0% | 0.21% | – |
| RVNC | Buy | Revance Therapeutics, Inc. | $6,059,000 | +180.8% | 213,808 | +149.1% | 0.21% | +163.0% |
| COGT | New | Cogent Biosciences, Inc. | $6,039,000 | – | 537,742 | +100.0% | 0.21% | – |
| SRRK | New | Scholar Rock Holding Corporation | $5,634,000 | – | 116,094 | +100.0% | 0.20% | – |
| VRNA | Buy | Verona Pharma plcsponsored adr | $5,263,000 | +77.4% | 751,905 | +58.2% | 0.18% | +66.7% |
| FMTX | New | Forma Therapeutics Holdings, Inc.shares | $5,229,000 | – | 149,825 | +100.0% | 0.18% | – |
| QURE | Buy | uniQure N.V.shares | $4,516,000 | +94.5% | 125,003 | +98.3% | 0.16% | +82.8% |
| ADUS | Buy | Addus HomeCare Corporation | $4,407,000 | +192.0% | 37,640 | +135.7% | 0.16% | +171.9% |
| PRAX | New | Praxis Precision Medicines, Inc. | $4,127,000 | – | 75,000 | +100.0% | 0.14% | – |
| AXNX | Buy | Axonics Modulation Technologies, Inc. | $4,032,000 | +307.3% | 80,760 | +316.3% | 0.14% | +283.8% |
| HLXA | New | Helix Acquisition Corp. | $2,708,000 | – | 250,000 | +100.0% | 0.10% | – |
| MIST | Buy | Milestone Pharmaceuticals Inc. | $1,699,000 | +8.8% | 253,610 | +18.9% | 0.06% | +3.4% |
| GRTS | New | Gritstone Oncology, Inc. | $1,651,000 | – | 419,005 | +100.0% | 0.06% | – |
| AFMD | New | Affimed N.V. | $1,560,000 | – | 268,019 | +100.0% | 0.06% | – |
| ALLO | New | Allogene Therapeutics, Inc. | $1,214,000 | – | 48,089 | +100.0% | 0.04% | – |
| VTRS | New | Viatris Inc. | $251,000 | – | 13,400 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.